Matchpoint is a privately held biotechnology company harnessing the power of covalency to discover precision oral medicines to transform the treatment of immune diseases. The company’s Advanced Covalent Exploration (ACE)TM platform integrates a suite of leading covalent drug discovery capabilities and is deployed toward validated, disease-causing protein targets that are yet undrugged or inadequately addressed by conventional approaches.